Hosted on MSN13h
William Blair Initiates Coverage of Mersana Therapeutics (MRSN) with Outperform Recommendation
Fintel reports that on February 6, 2025, William Blair initiated coverage of Mersana Therapeutics (NasdaqGS:MRSN) with a ...
Mersana Therapeutics initiated with an Outperform at William Blair
William Blair analyst Andy Hsieh last night initiated coverage of Mersana Therapeutics (MRSN) with an Outperform rating. The firm believes ...
Mersana Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference
CAMBRIDGE, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on ...
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Receives $5.57 Consensus Target Price from Analysts
Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN – Get Free Report) have been given a consensus rating of “Moderate Buy” by the eight analysts that are presently covering the company, Ratings reports ...
William Blair starts Mersana stock with Outperform rating
William Blair initiated coverage on Mersana Therapeutics, Inc. (NASDAQ:MRSN) with an Outperform rating. The firm's analyst cited the company's potential in the antibody-drug conjugates (ADCs) market ...
Business Insider7d
Mersana Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference
CAMBRIDGE, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of ...
Mena FN7d
Mersana Therapeutics To Participate In The Guggenheim SMID Cap Biotech Conference
(MENAFN- GlobeNewsWire - Nasdaq) CAMBRIDGE, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical ...